Genocea's phase 2 genital herpes data help 'de-risk' a larger trial set to start this year: analyst
admin 25th July 2017 Uncategorised 0Genocea shares already jumped after the company released 12-month topline data from a phase 2b study for its genital herpes therapeutic vaccine, but one analyst believes things may get a whole lot better at the biotech.
More: Genocea's phase 2 genital herpes data help 'de-risk' a larger trial set to start this year: analyst
Source: fierce